Mobile Site ›

Antibodies Against Citrullinated Peptides

A Role in the Diagnosis of Rheumatoid Arthritis



Subscribe

Receive notification when new Hot Topics are published:

Development of Clinical Assays for Anti-Citrullinated Protein Antibodies

Slide 11

September 2008

There have been several generations of anti-CCP assays. The first generation assay uses a cyclic peptide that happens to derive from the human filaggrin protein. Although this assay had improved sensitivity over the initial indirect immunofluorescent assays, the sensitivity was still poor in comparison to Rheumatoid factor. This type of assay was never widely used in most clinical laboratories.

The second generation anti-CCP antibody assay had significantly improved sensitivity primarily because these assays use a panel of citrullinated peptides that had been identified through screening of peptide libraries using serum from patients with Rheumatoid Arthritis. The second generation assays are still widely used as a clinical assay.

The third generation assays are relatively new and use a synthetic form of cyclic citrullinated peptide. The third generation assays are generally quite comparable to the second generation assays, although some studies have demonstrated a small improvement in sensitivity, primarily in patients with early disease.

Development of Clinical Assays

 


Jump to section:


Key